83 results
Page 3 of 5
PRER14A
juw 44hle
10 Apr 20
Preliminary revised proxy
4:38pm
8-K
EX-2.1
h7gbc4a
9 Mar 20
Entry into a Material Definitive Agreement
12:00am
DEFA14A
EX-2.1
120s8zjln
9 Mar 20
Additional proxy soliciting materials
12:00am
PREM14A
fnqrwhfhm yigy
6 Mar 20
Preliminary proxy related to merger
5:32pm
8-K
EX-2.1
3eji9j2 fiej
18 Dec 19
Zafgen and Chondrial Therapeutics Announce Definitive Merger Agreement
8:13am
DEFA14A
EX-2.1
n9w1l3a0k7d13bvjinct
18 Dec 19
Additional proxy soliciting materials
8:11am
CORRESP
c23f8kttjovs0gxygae
16 Nov 18
Correspondence with SEC
12:00am
8-K
EX-1.1
yga1u4iziigybsw3w
9 Nov 18
Entry into a Material Definitive Agreement
5:10pm
424B5
yjx2oh0yr6g
9 Nov 18
Prospectus supplement for primary offering
4:49pm
8-K
EX-1.1
zfkj3jge f6
28 Jun 18
Zafgen Announces Proposed Offering of Common Stock
5:01pm
424B5
4xnjrz7
28 Jun 18
Prospectus supplement for primary offering
4:54pm
424B5
s8g tdp97g
27 Jun 18
Prospectus supplement for primary offering
4:49pm
8-K
p3bjj2m ri
30 May 18
Zafgen, Inc. Expands Executive Leadership Team with Appointment of
5:17pm
8-K
EX-10.2
plqzx6thcmwnz61a4z
12 Oct 17
Zafgen Appoints Jeffrey Hatfield as Chief Executive Officer; Thomas Hughes, Ph.D. to Continue as President, Appointed Chief Scientific Officer
12:00am